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Malignant pleural effusions are frequently treated today by
instillation of tetracycline (Hausheer & Yarbro, 1985). The
hypothesis that the low pH of the tetracycline solution is the
reason for the therapeutic benefit (Sahn & Good, 1979)
could not be substantiated by a randomized study comparing
tetracycline with an acified multivitamin solution of similar
pH and aspect (Zaloznik et al., 1983). In recent experiments
we demonstrated cytostatic activity of decomposed tetra-
cycline and suggested that oxidation of the tetracycline
molecule is necessary for this cytostatic action (Sauter &
Cogoli, 1987). The present experiments were designed to
study the cytostatic activity of the three main degradation
products of tetracycline, i.e. anhydrotetracycline, 4-epi-
tetracycline, and 4-epi-anhydrotetracycline.
Tetracycline HCI, anhydrotetracycline HCI, 4-epi-
tetracycline HC1, and 4-epi-anhydrotetracycline HCl were
obtained from American Cyanamid Company, Lederle
Laboratories Division, USA. Heating of tetracycline HC1
(Sauter & Cogoli, 1987) was done after dissolving the drug
(500mg of tetracycline in 10ml distilled water).
A human hypernephroma line (Groscurth & Kistler, 1977)
was used as previously described (Sauter et al., 1986).
For inhibition of cell growth human hypernephroma cells
were incubated with the different tetracycline molecules in
the following way (Sauter & Cogoli, 1987): To 1 ml of
medium (RPMI 1640 supplemented with 8% foetal bovine
serum) containing a given drug concentration I ml of cell
suspension with - 120,000 hypernephroma cells freshly
prepared by trypsinization of a cell monolayer was added.
This mixture was incubated for 15min at 37°C in sterile 7ml
screw-capped centrifuge tubes. After incubation the cells
were centrifuged at 200g for 10min at 20°C, and then
resuspended in 4.2ml of fresh medium; 1.Oml of the cell
suspension was put in each of 4 wells of sterile flat bottom
plastic plates (24 wells, diameter 16mm, Costar, Cambridge,
Mass., USA). The plates were then incubated at 37°C in a
5% CO2 atmosphere. After 4 days of incubation - at this
time the control wells (only medium without drugs) showed
a complete monolayer containing - 1.3 x 106 cells per well -
the cells were stained by methylenblue/parafuchsin (Kistler &
Bischof, 1962) and the plates evaluated. In the case of
continuous drug contact to 1 ml of the original cell
suspension (- 120,000 cells), 1 ml of medium and 2ml of
drug dilution were added, thoroughly mixed, and also
distributed into 4 wells. There was no change of medium
until the end of the experiment after four days.
The evaluation of the stained plates was done over a neon
screen with a photographic light meter (Lunsix 3, Gossen,
FRG) containing an adapter piece fitting the 16mm wells of
the plastic plates. The results were recorded the following
way: Complete growth inhibition (Figure If) corresponded
to a light intensity (measured in lux) equal to that of plates
stained two hours after cell seeding. Detectable inhibition of
growth (Figure lb,e) corresponded to an increase of light
intensity of at least 25% in each well over the control wells.
Table 1 shows the concentrations necessary to produce







Figure 1 Growth inhibition by different tetracycline derivatives
(concentration 22pM); continuous exposure of a hypernephroma
cell line. a: Medium control: complete monolayer. b: Tetracycline
HCl, freshly prepared: detectable inhibition. c: Tetracycline
HCl, heated for 10min at 100°C: almost complete inhibition.
d: Anhydrotetracycline HCl: almost complete inhibition. e:
4-epi-tetracycline HCl: detectable inhibition. f: 4-epi-
anhydrotetracycline HCl: complete inhibition.
Table I Growth inhibition (GI) by tetracycline HCl, heated
tetracycline HCl, and three derivatives; continuous exposure of a
hypernephroma cell line
Minimal concentration (yM)for:
Drug complete GI detectable GI
Tetracycline HCl 44 22
Tetracycline HCl (100°C/10min) 44 11
Anhydrotetracycline HCl (AT) 44 11
4-epi-tetracycline HCl 44 22
4-epi-anhydrotetracycline HCl
(4-EAT) 22 11
growth inhibition of hypernephroma cells by tetracycline
either prepared freshly or heated for 10min at 100°C, and by
the three main degradation products. All of them cause
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growth inhibition at similar concentrations. The heated tetra-
cycline and the two oxidized molecules (anhydrotetracycline
and 4-epi-anhydrotetracycline) are only slightly more active
during continuous drug-cell contact. Figure 1 demonstrates
this difference: at a concentration of 22pM freshly prepared
tetracycline (b) and 4-epi-tetracycline (e) produce only
detectable growth inhibition whereas the heated tetracycline
and the anhydrotetracycline produce almost complete and
the 4-epi-anhydrotetracycline complete inhibition of growth.
At the same time Figure 1 illustrates the definitions of
complete and detectable inhibition of growth as described.
Table II shows that the non-oxidized molecules have no
cytostatic activity up to concentrations of 112jiM during
short time drug-cell contact.
Different drugs and techniques have been proposed for the
treatment of malignant effusions. Instillation of cytotoxic
drugs like bleomycin or nitrogen mustard is effective as well
as tube drainage and treatment with tetracycline (Hausheer
& Yarbro, 1985). The effect of tetracycline is ascribed to its
sclerosing effect (Sahn & Good, 1979). A study by Zaloznik
et al (1983) however, suggests an additional mechanism of
action since tetracycline treatment was more successful than
a sclerosing procedure alone. The present experiments
Table II Growth inhibition by tetracycline HCl, heated tetra-
cycline, and three derivatives: concentration 1121M; drug-cell
contact 15 minutes
Drug Growth inhibition
Tetracycline HCI, fresh none
Tetracycline HCl (100°C/0min) complete
Anhydrotetracycline HCI (AT) complete
4-epi-tetracycline HCI none
4-epi-anhydrotetracycline HCl (4-EAT) detectable
demonstrate that tetracycline - at least in its oxidized form -
is cytostatic. In the tetracycline vial (Achromycineg) ascorbic
acid is always added to prevent oxidation. In the pleural
cavity or by heating this protection of tetracycline by
ascorbic acid is rapidly lost. Oxidation products (anhydro-
tetracycline {AT} and 4-epi-anhydrotetracycline {4-EAT})
appear already after a few hours of incubation (Thomson et
al., 1984). The estimated concentrations of AT and 4-EAT in
the pleural cavity after the usual instillation of 1,000mg
tetracycline HCI must be at least 100 times higher than the
concentration required for complete growth inhibition of
tumour cells in vitro (see Table II).
The mechanism of cytostatic action of AT and 4-EAT can
presently only be a matter of speculation. AT and 4-EAT
resemble the anthracyclines in their structure being of a
biosynthetic origin similar to the tetracyclines (Hutchinson,
1981). Tetracycline binds to DNA (Kohn, 1961) and could,
therefore, act like anthracyclines as an intercalating agent.
The next obvious step will be to determine AT and 4-EAT
concentrations in pleural fluid and serum after tetracycline
instillation. Serum analysis may give an indication of
possible side effects known to be produced by degraded
tetracyclines (Frimpter et al., 1963). These determinations
will certainly be a prerequisite for the treatment of malignant
effusions by AT and 4-EAT. According to the in vitro results
these substances should be more efficient than the original
tetracycline molecule.
In conclusion, the therapeutic value of the tetracycline
treatments of malignant effusions may be due to a double
effect of tetracycline HCI, viz. a cytostatic and a sclerosing
action.
This work was supported by the 'Schweizerische Krebsliga'. I thank
Ms H. Ernst, Ms. Ch. Meier, and Ms. L. Resenterra for technical
assistance and Mrs. E. Sauter for linguistic help.
References
FRIMPTER, G.W., TIMPANELLI, A.E., EISENMENGER, W.J., STEIN,
H.S. & EHRLICH, L.I. (1963). Reversible 'Fanconi syndrome'
caused by degraded tetracycline. J. Am. Med. Assn., 184, 111.
GROSCURTH, P. & KISTLER, G.S. (1977). Human renal cell
carcinoma in the nude mouse: long term observations. Beitr.
Pathol., 160, 337.
HAUSHEER, F.H. & YARBRO, J.W. (1985). Diagnosis and treatment
ofmalignant pleural effusion. Sem. Oncol., 12, 54.
HUTCHINSON, C.R. (1981). The biosynthesis of tetracycline and
anthracycline antibiotics. In Antibiotics, Corcoran, J.W. (ed) Vol.
IV, p.1. Springer: Berlin.
KISTLER, G.S. & BISCHOFF, A. (1962). Zur exfoliativen Zytologie
kleiner Fliissigkeitsmengen. Schweiz. med. Wschr., 92, 863.
KOHN, K.W. (1961). Mediation of divalent metal ions in the binding
of tetracycline to macromolecules. Nature, 191, 1156.
SAHN, S.A. & GOOD, J.T. (1979). The pH of sclerosing agents. Chest,
76, 198.
SAUTER, Chr., COGOLI, M. & ARRENBRECHT, S. (1986). Interactions
of cytotoxic and other drugs: rapid cell culture assay. Oncology,
43, 46.
SAUTER, CHR. & COGOLI, M. (1987). Tetracycline in the treatment of
malignant effusions: evidence for a cytostatic action of the
decomposed drug. Eur. J. Cancer Clin. Oncol., 23, 973.
THOMSON, H.J., MERANI, S. & MILLER, S.S. (1984). Storage of
tetracycline solutions for peritoneal lavage. J. Royal Coll. Surg.
Edin., 29, 379.
ZALOZNIK, A.J., OXWALD, S.G. & LANGIN, M. (1983). Intrapleural
tetracycline in malignant pleural effusions. A randomized study.
Cancer, 51, 752.